DOI:
10.1055/s-00000031
Klinische Monatsblätter für Augenheilkunde
LinksClose Window
References
Ho AC, Busbee BG, Regillo CD. et al.
Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Ophthalmology 2014;
121: 2181-2192
We do not assume any responsibility for the contents of the web pages of other providers.